HGF2 Stock Overview
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Catalyst Biosciences, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$7.40 |
52 Week High | US$8.88 |
52 Week Low | US$2.36 |
Beta | 1.29 |
1 Month Change | 12.13% |
3 Month Change | 63.12% |
1 Year Change | -10.64% |
3 Year Change | -89.32% |
5 Year Change | -94.67% |
Change since IPO | -99.87% |
Recent News & Updates
Recent updates
Shareholder Returns
HGF2 | DE Biotechs | DE Market | |
---|---|---|---|
7D | 25.8% | 1.2% | 2.5% |
1Y | -10.6% | 34.7% | 7.0% |
Return vs Industry: HGF2 exceeded the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: HGF2 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
HGF2 volatility | |
---|---|
HGF2 Average Weekly Movement | 22.1% |
Biotechs Industry Average Movement | 5.7% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: HGF2's share price has been volatile over the past 3 months.
Volatility Over Time: HGF2's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2002 | 7 | Nassim Usman | https://www.catalystbiosciences.com |
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.
Catalyst Biosciences, Inc. Fundamentals Summary
HGF2 fundamental statistics | |
---|---|
Market cap | €18.35m |
Earnings (TTM) | -€41.80m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs HGF2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
HGF2 income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$1.97m |
Gross Profit | -US$1.97m |
Other Expenses | US$42.27m |
Earnings | -US$44.24m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -17.47 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did HGF2 perform over the long term?
See historical performance and comparison